Options
Perera-Bel, Júlia
Loading...
Preferred name
Perera-Bel, Júlia
Official Name
Perera-Bel, Júlia
Alternative Name
Perera-Bel, Julia
Perera-Bel, J.
Main Affiliation
Now showing 1 - 1 of 1
2018Journal Article [["dc.bibliographiccitation.firstpage","18"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Genome Medicine"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Perera-Bel, Júlia"],["dc.contributor.author","Hutter, Barbara"],["dc.contributor.author","Heining, Christoph"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Fröhlich, Martina"],["dc.contributor.author","Fröhling, Stefan"],["dc.contributor.author","Glimm, Hanno"],["dc.contributor.author","Brors, Benedikt"],["dc.contributor.author","Beißbarth, Tim"],["dc.date.accessioned","2019-01-25T08:41:44Z"],["dc.date.available","2019-01-25T08:41:44Z"],["dc.date.issued","2018"],["dc.description.abstract","A comprehensive understanding of cancer has been furthered with technological improvements and decreasing costs of next-generation sequencing (NGS). However, the complexity of interpreting genomic data is hindering the implementation of high-throughput technologies in the clinical context: increasing evidence on gene-drug interactions complicates the task of assigning clinical significance to genomic variants."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2018"],["dc.identifier.doi","10.1186/s13073-018-0529-2"],["dc.identifier.pmid","29544535"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15160"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57380"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/15091 but duplicate"],["dc.notes.status","zu prüfen"],["dc.relation.eissn","1756-994X"],["dc.rights","CC BY 4.0"],["dc.rights.access","openAccess"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","From somatic variants towards precision oncology: Evidence-driven reporting of treatment options in molecular tumor boards"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]Details DOI PMID PMC